🇺🇸 Methyl B12 in United States

59 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 59

Most-reported reactions

1. Headache — 10 reports (16.95%)
2. Insomnia — 8 reports (13.56%)
3. Arthralgia — 6 reports (10.17%)
4. Dizziness — 6 reports (10.17%)
5. Vomiting — 6 reports (10.17%)
6. Drug Ineffective — 5 reports (8.47%)
7. Fatigue — 5 reports (8.47%)
8. Nausea — 5 reports (8.47%)
9. Asthenia — 4 reports (6.78%)
10. Fall — 4 reports (6.78%)

Source database →

Frequently asked questions

Is Methyl B12 approved in United States?

Methyl B12 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Methyl B12 in United States?

University of California, San Francisco is the originator. The local marketing authorisation holder may differ — check the official source linked above.